Personalized mRNA vaccine plus Keytruda shows promising Phase 3 melanoma results
Moderna and Merck report that adding the patient-specific mRNA cancer vaccine intismeran (mRNA-4157) to Merck’s Keytruda significantly extended recurrence-free and distant metastasis-free survival versus Keytruda alone in a Phase 3 trial of 1,137 melanoma patients. Interim results suggest meaningful benefit, with mature overall-survival data still pending; five-year Phase 2 data had previously shown substantial risk reductions. Full details will be presented at an upcoming conference.